Helomics, a privately held, healthcare company providing personalized medicine solutions for clients in the pharmaceutical, diagnostic and biotech industries, has announced the completion of the final phase of its corporate realignment toward becoming a fully-integrated clinical contract research and clinical products organization (ICCRO).  

As an ICCRO, Helomics will provide product enhancement and clinical laboratory services, including comprehensive tumor profiling utilizing proprietary cell-based products and services, to strategic partners in the healthcare industries. The new business model will continue to offer and enhance the company’s clinical laboratory test menu, leveraging core scientific strengths, to provide physicians with relevant clinical information to better inform their patient treatment decisions. Now, patients who consent to sample testing at Helomics have the opportunity to further cancer research and the development of new therapies and diagnostic methods through Helomics’ innovative technology development and industry partnerships.

Gerald J. Vardzel Jr., will serve as the president and CEO. With over 25 years of industry experience, Vardzel has guided many innovative products through validation and commercialization, perfecting tried and tested strategies in both start-up and established settings. Vardzel said, “It is a pleasure for me to serve in this leadership role for Helomics. Helomics has a history of commitment to cutting-edge science to improve patient care. This corporate realignment will allow us to focus on partnerships with pharmaceutical and diagnostic companies to enable innovative therapies and diagnostic technologies in the marketplace.”